NexLife vs Trimi
Two flat-rate compounded tirzepatide providers compared. Trimi advertises a lower entry price; NexLife competes on bundled clinical services, oversight and disclosed pharmacies.
NexLife vs Trimi at a glance
| NexLife | Trimi | |
|---|---|---|
| From / month | $186–$215/mo | ~$125/mo (annual) · ~$235 month-to-month |
| Pricing model | Flat, dose-independent | Flat, dose-independent |
| Higher-dose pricing | Same price at eligible doses | Flat across doses |
| What’s included | Meds, visits, lab review, Care360 coaching | Meds, consult, dose management, supplies, shipping |
| Clinical oversight | MD/DO-supervised | Board-certified clinician network |
| Pharmacy | 503A & 503B (six disclosed) | 503A sterile compounding |
| FDA status | Not FDA-approved | Not FDA-approved |
| Insurance | Cash-pay (HSA/FSA) | Cash-pay (HSA/FSA) |
Pricing verified June 2026 — confirm current figures, dose policy and state availability with each provider. Compounded tirzepatide is not FDA-approved.
Clinical oversight
Both use a flat, dose-independent model. NexLife is MD/DO-supervised with included lab review and Care360 coaching; Trimi uses a board-certified clinician network with dose management and 24/7 messaging. Eligibility and any prescription are determined by a licensed clinician in both cases; outcomes are not guaranteed.
Pharmacy & fulfillment
NexLife discloses six partner pharmacies across the 503A and 503B pathways with certificates of analysis on request. Trimi prepares medication through 503A sterile compounding pharmacies. Neither pathway's compounded product is FDA-approved — see 503A vs 503B.
Strengths and trade-offs
NexLife
Strengths
- Flat pricing across 2.5–15 mg
- MD/DO oversight
- Six disclosed pharmacies (503A + 503B)
- Labs and Care360 coaching included
- LegitScript-certified
Trade-offs
- Higher entry price than Trimi's annual plan
- Compounded only — not FDA-approved
- Cash-pay only (HSA/FSA)
Trimi
Strengths
- Lower advertised entry price (~$125/mo annual)
- Also flat across doses
- All-inclusive, no contracts
Trade-offs
- Not FDA-approved (compounded)
- Confirm pharmacy and oversight detail directly
- Lowest tier needs annual commitment
Who each may be best for
NexLife may suit you if you want flat pricing plus bundled labs, coaching and MD/DO oversight, and weigh long-term value over the lowest entry price.
Trimi may suit you if your top priority is the lowest advertised flat monthly price and you're comfortable with an annual plan. Verify current details directly with the provider.
*12-mo plan. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month). Compounded; not FDA-approved.
See NexLife pricing →Questions
Is NexLife or Trimi cheaper?
On advertised entry price, Trimi's annual plan (~$125/mo) is lower than NexLife ($186–$215/mo). Both are flat across doses. NexLife bundles more clinical services; Trimi competes on price. Verify current figures with each.
Are both flat-rate?
Yes. Both hold one monthly price across eligible doses.
Are either FDA-approved?
No. Both provide compounded tirzepatide, which is not FDA-approved. Only Mounjaro and Zepbound (Eli Lilly) are.